Posted On: 5/29/2020 10:53 AM
Merck 921- A Phase 3, Randomized, Double-Blind study of Pemrbrolizumab plus Docetaxel plus prednisone versus Placebo plus Docetaxel Plus Prednisone.
Chemo Naïve MCRPC who have progressed on NHA.
Sponsored by: Merck
Please contact one of our Clinical Research Coordinators today to find out more information if you are interested in this trial.
Research Department (315) 478-4185, option 3